



UBS Warburg Global Specialty Pharmaceuticals Conference to Webcast Alkermes' Corporate Presentation

June 2, 2003

CAMBRIDGE, Mass.--(BUSINESS WIRE)--June 2, 2003--Alkermes, Inc. (NASDAQ: ALKS) announced today that its corporate presentation will be webcast live by UBS Warburg on Wednesday, June 4, 2003 at 2:00pm EDT from the Grand Hyatt Hotel at Grand Central Station in New York. The presentation may be accessed under the investor relations tab at www.alkermes.com and will be archived for 14 days.

Alkermes, Inc. is an emerging pharmaceutical company developing products based on its sophisticated drug delivery technologies to enhance therapeutic outcomes. Our areas of focus include: controlled, extended-release of injectable drugs utilizing our ProLease(R) and Medisorb(R) delivery systems and the development of inhaled pharmaceutical products based on our proprietary Advanced Inhalation Research, Inc. ("AIR(R)") pulmonary delivery system. Our business strategy is twofold. We partner our proprietary technology systems and drug delivery expertise with many of the world's finest pharmaceutical companies and also develop novel, proprietary drug candidates for our own account. In addition to our Cambridge, Massachusetts headquarters, research and manufacturing facilities, we operate research and manufacturing facilities in Ohio.

CONTACT: Rebecca Peterson
Director, Corporate Communications
Alkermes, Inc.
(617) 583-6378